KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic Acid.

Andres Yarur, Peter Irving, Britta Siegmund, Marla C Dubinsky, Ashwin N Ananthakrishnan, Miguel Regueiro, Ryan C Ungaro, Timothy Ritter, Hiroshi Nakase, Zhaohui Liu, Dimpy Mehra, Mark T Osterman, Anjali Jain, David T Rubin, Toshifumi Hibi

Inflamm Bowel Dis 32(1) 77-86

PMID41003640
PMCIDPMC12759051
DOI10.1093/ibd/izaf195
发表日期2025-09-26
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 6 张 PMC Figure,均未识别为 KM 图:Figure 1.:AI 判定为 flow diagram;Figure 2.:非 KM 图;Figure 3.:非 KM 图;Figure 4.:非 KM 图;Figure 5.:非 KM 图;另有 1 张未列出。
摘要

摘要

BACKGROUND: We evaluated the efficacy and safety of ozanimod after 5-aminosalicylic acid (5-ASA) failure in advanced therapy (AT)-naive patients with moderate ulcerative colitis (UC) in True North and its open-label extension (OLE). METHODS: True North was a randomized, 52-week, phase 3 trial with an optional OLE. Efficacy was assessed in True North and the OLE; safety was assessed through OLE week 190. RESULTS: Overall, 203 AT-naive True North patients had moderate UC (Mayo endoscopic subscore of 2 + modified Mayo score of 4-6 + rectal bleeding subscore ≥1). Of these, 139 were also immunomodulator-naive and not receiving corticosteroids (5-ASA-exposed only) at baseline. Patients with moderate UC receiving ozanimod vs placebo achieved greater efficacy rates for all week 10 and week 52 outcomes, regardless of prior immunomodulator/corticosteroid use (eg, week 10 clinical remission: AT-naive = 36.8% vs 10.6%; 5-ASA-exposed only = 37.9% vs 17.2%). Higher symptomatic response rates were achieved by week 2 with ozanimod in AT-naive patients with moderate UC vs the overall AT-naive population (50.5% vs 38.7%); similar trends were observed in patients exposed only to 5-ASA. Efficacy was maintained through OLE week 190 in patients who entered OLE as True North week 52 ozanimod clinical responders. Of those entering OLE as True North week 10 ozanimod clinical nonresponders, 69.0% of AT-naive patients and 68.4% of patients exposed only to 5-ASA achieved symptomatic response by week 5. No new safety signals emerged. CONCLUSIONS: Ozanimod was safe, effective, and durable up to ∼5 years in AT-naive patients with moderate UC who failed conventional therapy. ClinicalTrials.gov: NCT02435992, NCT02531126.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Disposition for the True North advanced therapy (AT)–naive patients with moderate ulcerative colitis (UC). Moderate UC is defined as a Mayo endoscopic subscore of 2 + modified Mayo score of 4-6 + rectal bleeding subscore ≥1. OLE, open-label extension.
非 KM Figure
Figure 2.Symptomatic efficacy through week 10 in cohort 1 of the True North induction period in advanced therapy (AT)–naive patients and patients exposed only to 5-aminosalicylic acid (5-ASA). (A) Symptomatic response in AT-naive patients with moderate ulcerative colitis (UC) (Mayo endoscopic subscore of 2 + modified Mayo score of 4-6 + rectal bleeding subscore ≥1). (B) Symptomatic response in the overall AT-naive patients. Shading indicates the 1-week dose escalation period of ozanimod. * P < .05, ** P < .01, *** P < .001.
非 KM Figure
Figure 3.Efficacy outcomes at week 10 in patients with moderate ulcerative colitis (UC; Mayo endoscopic subscore of 2 + modified Mayo score of 4-6 + rectal bleeding subscore ≥1) and in the overall population who were advanced therapy (AT)–naive or exposed only to 5-aminosalicylic acid (5-ASA). (A) Clinical remission. (B) Clinical response. (C) Endoscopic improvement. (D) Mucosal healing. Δ refers to the difference between ozanimod (cohort 1) and placebo in the induction period. * P < .05, ** P < .01, *** P < .001 vs placebo. CI, confidence interval.
非 KM Figure
Figure 4.Efficacy outcomes at week 52 in patients with moderate ulcerative colitis (UC; Mayo endoscopic subscore of 2 + modified Mayo score of 4-6 + rectal bleeding subscore ≥1) and in the overall population who were advanced therapy (AT)–naive or exposed only to 5-aminosalicylic acid (5-ASA). (A) Clinical remission. (B) Clinical response. (C) Endoscopic improvement. (D) Mucosal healing. * P < .05, ** P < .01, *** P < .001 vs placebo. CI, confidence interval.
非 KM Figure
Figure 5.Efficacy through True North open-label extension (OLE) study week 190 in patients with moderate ulcerative colitis (UC; Mayo endoscopic subscore of 2 + modified Mayo score of 4-6 + rectal bleeding subscore ≥1) and in the overall population who were advanced therapy (AT)–naive or exposed only to 5-aminosalicylic acid (5-ASA) and who entered the OLE as True North week 52 ozanimod clinical responders (observed case [OC] analysis). (A) Clinical remission. (B) Endoscopic improvement.
非 KM Figure
Figure 6.Symptomatic efficacy with up to 10 weeks of extended induction in the True North open-label extension (OLE) study in patients with moderate ulcerative colitis (UC; Mayo endoscopic subscore of 2 + modified Mayo score of 4-6 + rectal bleeding subscore ≥1) and in the overall population who were advanced therapy (AT)–naive or exposed only to 5-aminosalicylic acid (5-ASA) and who entered the OLE as clinical nonresponders at True North week 10 (observed case [OC] analysis). (A) Symptomatic response. (B) Symptomatic remission.
非 KM Figure